Lansoprazole NDC 0378-6982

NDC codes

FDA NDC Directory

Product NDC (as listed)0378-6982Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00378-6982Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0378-6982-88	00378698288	2 CARTON in 1 BOX (0378-6982-88) / 5 BLISTER PACK in 1 CARTON (0378-6982-85) / 10 TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE in 1 BLISTER PACK (0378-6982-32)Marketed from Nov 29, 2018

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lansoprazole
Generic name (nonproprietary): lansoprazole
Active ingredients: Lansoprazole — 30 mg/1
Dosage form: Tablet, Orally disintegrating, Delayed release
Route: Oral
Labeler: Mylan Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202396
Marketing start: Nov 29, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Inhibition Gastric Acid Secretion (Physiologic effect)Proton Pump Inhibitors (Mechanism)
Identifiers: Product ID 0378-6982_00959575-41db-4810-b59c-1edd08568b17SPL ID 00959575-41db-4810-b59c-1edd08568b17SPL set ID 20ff347c-ca18-497b-948d-1145035f2ffcRxCUI 351260, 351261UNII 0K5C5T2QPG
Pharmacologic class: Proton Pump Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400378698288 followed by a unit qualifier and the quantity

Package 00378-6982-88. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 11, 2024.

Indications (excerpt from the label)

Lansoprazole delayed-release orally disintegrating tablets are a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) • Treatment o…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202396

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202396
Product	Strength	Form · route	Labeler	Product NDC
Lansoprazole	Lansoprazole 15 mg/1	Tablet, Orally disintegrating, Delayed releaseOral	Mylan Pharmaceuticals Inc.	0378-6981